|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
AU2015259877B2
(en)
|
2014-05-15 |
2021-02-25 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
KR20170042598A
(ko)
*
|
2014-08-22 |
2017-04-19 |
셀진 코포레이션 |
항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
|
|
AU2015355188B2
(en)
|
2014-12-01 |
2021-08-26 |
Northeast Ohio Medical University |
CAMKK1 as a novel regenerative therapeutic
|
|
CA2973878A1
(en)
|
2015-01-22 |
2016-07-28 |
University Of Massachusetts |
Cancer immunotherapy
|
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
US12590321B2
(en)
|
2016-03-19 |
2026-03-31 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
GB2567093A
(en)
|
2016-07-15 |
2019-04-03 |
Viracta Therapeutics Inc |
Histone deacetylase inhibitors for use in immunotherapy
|
|
SG10201912663YA
(en)
|
2016-10-11 |
2020-03-30 |
Agenus Inc |
Anti-lag-3 antibodies and methods of use thereof
|
|
CA3037046A1
(en)
*
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
|
WO2018106862A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
|
EP3581190B1
(en)
|
2016-12-09 |
2021-03-10 |
ONK Therapeutics Limited |
Engineered natural killer cells and uses thereof
|
|
CN108277205B
(zh)
*
|
2016-12-30 |
2022-12-20 |
四川大学 |
表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途
|
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための組成物および方法
|
|
KR102660336B1
(ko)
|
2017-03-27 |
2024-04-26 |
내셔널 유니버시티 오브 싱가포르 |
절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
|
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
|
US12129487B2
(en)
*
|
2017-03-27 |
2024-10-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to obtain lymphoid progenitors
|
|
WO2018218151A1
(en)
*
|
2017-05-25 |
2018-11-29 |
University Of Central Florida Research Foundation, Inc. |
Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
|
|
TWI676483B
(zh)
*
|
2017-08-06 |
2019-11-11 |
強普生技股份有限公司 |
醫藥套組及其用途
|
|
CA3077325A1
(en)
*
|
2017-09-28 |
2019-04-04 |
Celularity Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
|
IL273757B2
(en)
|
2017-10-02 |
2025-01-01 |
Gamida Cell Ltd |
Growing and using NK cell populations
|
|
CA3080109A1
(en)
*
|
2017-11-03 |
2019-05-09 |
Sorrento Therapeutics, Inc. |
Cd38-directed chimeric antigen receptor constructs
|
|
SG11202005557TA
(en)
*
|
2017-12-12 |
2020-07-29 |
Macrogenics Inc |
Bispecific cd 16-binding molecules and their use in the treatment of disease
|
|
CN108060137B
(zh)
*
|
2017-12-26 |
2021-07-02 |
博生吉医药科技(苏州)有限公司 |
Il7和il21修饰的nk92细胞、制备方法及其应用
|
|
WO2019127215A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
TR201900059A2
(tr)
*
|
2018-01-05 |
2019-07-22 |
Gnt Biotech & Medicals Corp |
Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞の使用方法
|
|
US11814623B2
(en)
|
2018-01-30 |
2023-11-14 |
University Of Massachusetts |
Methods of treating a wound using epigenetic regulation
|
|
EP3746095A4
(en)
|
2018-02-01 |
2021-04-21 |
Nkmax Co., Ltd. |
Method of producing natural killer cells and composition for treating cancer
|
|
AU2019219454A1
(en)
|
2018-02-09 |
2020-08-27 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
WO2019183094A1
(en)
*
|
2018-03-19 |
2019-09-26 |
The Regents Of The University Of Michigan |
Compositions and methods for t-cell and cytokine activation
|
|
CN112055717B
(zh)
|
2018-04-02 |
2024-04-26 |
新加坡国立大学 |
用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
|
|
EP3781182A4
(en)
|
2018-04-18 |
2021-11-17 |
Summa Health |
COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA
|
|
WO2019200586A1
(en)
*
|
2018-04-19 |
2019-10-24 |
The Chinese University Of Hong Kong |
Modified nk cells and uses thereof
|
|
GB201807050D0
(en)
*
|
2018-04-30 |
2018-06-13 |
Cellprotect Nordic Pharmaceuticals Ab |
Medical uses
|
|
KR102373502B1
(ko)
|
2018-05-14 |
2022-03-11 |
주식회사 금호에이치티 |
골수유래억제세포 관련 질환의 예방 및 치료 용도
|
|
KR102069704B1
(ko)
*
|
2018-05-16 |
2020-01-23 |
고려대학교 산학협력단 |
Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법
|
|
JP2021525066A
(ja)
*
|
2018-05-30 |
2021-09-24 |
グリコステム セラピューティクス ベスローテン フェンノートシャップ |
Ｃａｒ ｎｋ細胞
|
|
WO2019240934A1
(en)
|
2018-06-12 |
2019-12-19 |
Promab Biotechnologies, Inc. |
Plap-car-effector cells
|
|
CN108815186A
(zh)
*
|
2018-06-14 |
2018-11-16 |
上海鸣大生物科技有限公司 |
一种治疗hpv持续感染引起疾病的药物及制备方法与应用
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
WO2020051248A1
(en)
*
|
2018-09-05 |
2020-03-12 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic virus platform to treat hematological cancer
|
|
WO2020081841A1
(en)
|
2018-10-19 |
2020-04-23 |
Regents Of The University Of Minnesota |
Nk engager molecules and methods of use thereof
|
|
SG11202104524YA
(en)
|
2018-11-01 |
2021-05-28 |
Gracell Biotechnologies Shanghai Co Ltd |
Compositions and methods for t cell engineering
|
|
US12590148B2
(en)
|
2018-11-26 |
2026-03-31 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
JP2022513164A
(ja)
*
|
2018-11-30 |
2022-02-07 |
セルラリティ インク． |
胎盤由来同種ｃａｒ－ｔ細胞およびその使用
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
JP2022525928A
(ja)
*
|
2019-03-21 |
2022-05-20 |
ガミダ セル リミテッド |
併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
|
|
EP3962527A4
(en)
|
2019-04-30 |
2023-11-01 |
Senti Biosciences, Inc. |
CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
|
|
US20220273716A1
(en)
*
|
2019-07-25 |
2022-09-01 |
Celularity Inc. |
Populations of natural killer cells comprising a cd38 chimeric antigen receptor
|
|
JP2022546101A
(ja)
*
|
2019-09-01 |
2022-11-02 |
エクスマ バイオテック コーポレイション |
リンパ球の改変および送達のための方法および組成物
|
|
EP4041256A4
(en)
*
|
2019-10-10 |
2023-11-08 |
Arizona Board of Regents on behalf of Arizona State University |
Oncolytic viruses that express multi-specific immune cell engagers
|
|
EP4065144A4
(en)
*
|
2019-11-27 |
2024-04-10 |
Deverra Therapeutics Inc. |
COMPOSITIONS AND METHODS FOR CULTIVATION OF HEMATOPOETIC STEM CELLS AND PROGENITOR CELLS
|
|
US20230212515A1
(en)
*
|
2019-11-28 |
2023-07-06 |
Glycostem Therapeutics B.V. |
Method for obtaining car-nk cells
|
|
EP4114400A4
(en)
*
|
2020-03-05 |
2023-10-18 |
Exuma Biotech Corp. |
Methods and compositions for the delivery of modified lymphocyte aggregates
|
|
WO2021188836A1
(en)
*
|
2020-03-18 |
2021-09-23 |
Barron Annelise E |
Upregulation of cathelicidin gene expression as an adjuvant to other treatments for diseases
|
|
JP2023541694A
(ja)
*
|
2020-09-22 |
2023-10-03 |
ワールド バイオテック リジェネラティブ メディカル グループ リミテッド |
がん治療剤としての二重特異的抗原結合分子を有するｃａｒ発現ナチュラルキラー細胞の生成方法及び組成物
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
EP4291028A1
(en)
*
|
2021-02-09 |
2023-12-20 |
Takeda Pharmaceutical Company Limited |
Methods and compositions for freezing and thawing mammalian cells
|
|
AR124837A1
(es)
|
2021-02-09 |
2023-05-10 |
Millennium Pharm Inc |
Métodos y composiciones para congelar y descongelar células de mamíferos
|
|
CN113398264B
(zh)
*
|
2021-08-06 |
2022-04-29 |
朱有建 |
Nk细胞及其组合物在治疗癌症中的用途
|
|
CN118119636A
(zh)
*
|
2021-08-10 |
2024-05-31 |
盖米达细胞有限公司 |
抗her2 car nk细胞、它们的生产方法及其用途
|
|
CN113577267B
(zh)
*
|
2021-09-06 |
2022-04-08 |
江西北正干细胞生物科技有限公司 |
Nk细胞和抗体的药物组合物及其在治疗癌症中的用途
|
|
KR20240063899A
(ko)
*
|
2021-09-08 |
2024-05-10 |
가부시키가이샤 가이아바이오메디신 |
세포의 처리 방법
|
|
EP4180049A1
(en)
*
|
2021-11-16 |
2023-05-17 |
Ostravska univerzita |
Therapeutic composition for cancer treatment
|
|
CN114058584B
(zh)
*
|
2022-01-07 |
2022-07-01 |
山东省齐鲁干细胞工程有限公司 |
一种临床用自然杀伤细胞的制备方法
|
|
CN115927169B
(zh)
*
|
2022-10-11 |
2023-08-11 |
再造再生医学科技(杭州)有限公司 |
用于扩增cd34+造血干细胞的培养液和体外扩增cd34+造血干细胞的方法
|
|
CN119082021B
(zh)
*
|
2024-09-30 |
2025-03-28 |
广东壹加再生医学研究院有限公司 |
一种增强型nk细胞及其制备方法
|
|
CN119280423A
(zh)
*
|
2024-10-10 |
2025-01-10 |
中南大学 |
一种联合靶向鼻咽癌治疗的载药体系及其制备方法与应用
|
|
CN121378506A
(zh)
*
|
2025-10-21 |
2026-01-23 |
北京京科信拓生物技术有限公司 |
表达car的免疫细胞及其应用
|